The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment

Bader, Rebecca A.

doi:10.5772/26155

Cited by 1 publication

(1 citation statement)

References 103 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the nanoparticles may undergo surface modification to enhance their specificity and therapeutic effectiveness by conjugating with antibodies, peptides, or polysaccharides that specifically target the receptors present in the afflicted tissue of RA. By integrating passive and active targeting techniques, medication delivery may be optimized, resulting in reduced toxicity and undesired side effects, ultimately enhancing patient outcomes, and, thus, imparting success to the nanoparticles’ drug delivery approach [ 61 , 106 ].…”

Section: Potential Role Of Nanotechnology In Delivery Of Dmardsmentioning

confidence: 99%

Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management

Singh,

Tiwary,

Sharma

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Disease-modifying anti-rheumatic drugs (DMARDs) is a class of anti-rheumatic medicines that are frequently prescribed to patients suffering from rheumatoid arthritis (RA). Methotrexate, sulfasalazine, hydroxychloroquine, and azathioprine are examples of non-biologic DMARDs that are being used for alleviating pain and preventing disease progression. Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs. This review article delineates the classification of DMARDs and their characteristic attributes. The poor aqueous solubility or permeability causes the limited oral bioavailability of synthetic DMARDs, while the high molecular weights along with the bulky structures of bDMARDs have posed few obstacles in their drug delivery and need to be addressed through the development of nanoformulations like cubosomes, nanospheres, nanoemulsions, solid lipid nanoparticles, nanomicelles, liposome, niosomes, and nanostructured lipid carrier. The main focus of this review article is to highlight the potential role of nanotechnology in the drug delivery of DMARDs for increasing solubility, dissolution, and bioavailability for the improved management of RA. This article also focusses on the different aspects of nanoparticles like their applications in biologics, biocompatibility, body clearance, scalability, drug loading, and stability issues.

show abstract

Section: Potential Role Of Nanotechnology In Delivery Of Dmardsmentioning

confidence: 99%